For Argentino Calvo, a retired firefighter and paramedic from Bluffton, South Carolina, joining a COVID-19 vaccine trial was not just a personal choice but an investment in the health of his community.
Calvo participated in the Novavax vaccine trial at MUSC, which was part of a large-scale study that recruited over 30,000 patients across 119 study sites in the United States and Mexico. SCTR co-principal investigator Patrick Flume, M.D. is leading MUSC’s studies on vaccine candidates, which includes the Novavax vaccine trial.
- Medical University of South Carolina
- COVID-19 vaccines
- clinical trials
Publishing CTSA Program Hub’s Name
Medical University Of South Carolina
CTSA Program In Action Goals
Goal 2: Engage Patients and Communities in Every Phase of the Translational Process
Goal 3: Promote the Integration of Special and Underserved Populations in Translational Research Across the Human Lifespan